当前位置: 首页 >> 检索结果
361. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
作者: Barry A Borlaug.;John Blair.;Martin W Bergmann.;Heiko Bugger.;Dan Burkhoff.;Leonhard Bruch.;David S Celermajer.;Brian Claggett.;John G F Cleland.;Donald E Cutlip.;Ira Dauber.;Jean-Christophe Eicher.;Qi Gao.;Thomas M Gorter.;Finn Gustafsson.;Chris Hayward.;Jan van der Heyden.;Gerd Hasenfuß.;Scott L Hummel.;David M Kaye.;Jan Komtebedde.;Joseph M Massaro.;Jeremy A Mazurek.;Scott McKenzie.;Shamir R Mehta.;Mark C Petrie.;Marco C Post.;Ajith Nair.;Andreas Rieth.;Frank E Silvestry.;Scott D Solomon.;Jean-Noël Trochu.;Dirk J Van Veldhuisen.;Ralf Westenfeld.;Martin B Leon.;Sanjiv J Shah.; .
来源: Circulation. 2022年145卷21期1592-1604页
In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit.
362. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.
作者: Yaling Han.;Bimmer E Claessen.;Shao-Liang Chen.;Qiu Chunguang.;Yujie Zhou.;Yawei Xu.;Lin Hailong.;Jiyan Chen.;Wu Qiang.;Ruiyan Zhang.;Suxin Luo.;Yongjun Li.;Jianhua Zhu.;Xianxian Zhao.;Xiang Cheng.;Jian'an Wang.;Xi Su.;Jianhong Tao.;Yingxian Sun.;Geng Wang.;Yi Li.;Liya Bian.;Ridhima Goel.;Samantha Sartori.;Zhongjie Zhang.;Dominick J Angiolillo.;David J Cohen.;C Michael Gibson.;Adnan Kastrati.;Mitchell Krucoff.;Shamir R Mehta.;E Magnus Ohman.;Philippe Gabriel Steg.;Yuqi Liu.;George Dangas.;Samin Sharma.;Usman Baber.;Roxana Mehran.
来源: Circ Cardiovasc Interv. 2022年15卷4期e009495页
The risk/benefit tradeoff of dual antiplatelet therapy after percutaneous coronary intervention may vary in East Asian patients as compared with their non-East Asian counterparts.
363. Short-Term Postoperative Use of Rivaroxaban to Prevent Radial Artery Occlusion After Transradial Coronary Procedure: The RESTORE Randomized Trial.
作者: Dongjie Liang.;Qingcheng Lin.;Qianli Zhu.;Xiaodong Zhou.;Ying Fang.;Liangguo Wang.;Guangze Xiang.;Kenneth I Zheng.;Weijian Huang.;Peiren Shan.
来源: Circ Cardiovasc Interv. 2022年15卷4期e011555页
Adequate procedural anticoagulation is crucial for radial artery occlusion (RAO) prevention in patients undergoing transradial access coronary catheterization, although the effect of postprocedural anticoagulation lack thorough investigation. The aim of this study was to evaluate the clinical value of short-term postoperative anticoagulation with rivaroxaban for 24 hours and 1-month RAO prevention in patients who received transradial coronary procedures.
364. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.
作者: Ratika Parkash.;George A Wells.;Jean Rouleau.;Mario Talajic.;Vidal Essebag.;Allan Skanes.;Stephen B Wilton.;Atul Verma.;Jeffrey S Healey.;Laurence Sterns.;Matthew Bennett.;Jean-Francois Roux.;Lena Rivard.;Peter Leong-Sit.;Mats Jensen-Urstad.;Umjeet Jolly.;Francois Philippon.;John L Sapp.;Anthony S L Tang.
来源: Circulation. 2022年145卷23期1693-1704页
Atrial fibrillation (AF) and heart failure (HF) frequently coexist and can be challenging to treat. Pharmacologically based rhythm control of AF has not proven to be superior to rate control. Ablation-based rhythm control was compared with rate control to evaluate if clinical outcomes in patients with HF and AF could be improved.
365. Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study.
作者: Ka-Chun Li.;Liping Huang.;Maoyi Tian.;Gian Luca Di Tanna.;Jie Yu.;Xinyi Zhang.;Xuejun Yin.;Yishu Liu.;Zhixin Hao.;Bo Zhou.;Xiangxian Feng.;Zhifang Li.;Jianxin Zhang.;Jixin Sun.;Yuhong Zhang.;Yi Zhao.;Ruijuan Zhang.;Yan Yu.;Nicole Li.;Lijing L Yan.;Darwin R Labarthe.;Paul Elliott.;Yangfeng Wu.;Bruce Neal.;Thomas Lung.;Lei Si.
来源: Circulation. 2022年145卷20期1534-1541页
SSaSS (Salt Substitute and Stroke Study), a 5-year cluster randomized controlled trial, demonstrated that replacing regular salt with a reduced-sodium, added-potassium salt substitute reduced the risks of stroke, major adverse cardiovascular events, and premature death among individuals with previous stroke or uncontrolled high blood pressure living in rural China. This study assessed the cost-effectiveness profile of the intervention.
366. Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA.
作者: Daniel B Mark.;John A Spertus.;Robert Bigelow.;Sophia Anderson.;Melanie R Daniels.;Kevin J Anstrom.;Khaula N Baloch.;David J Cohen.;Claes Held.;Shaun G Goodman.;Sripal Bangalore.;Derek Cyr.;Harmony R Reynolds.;Karen P Alexander.;Yves Rosenberg.;Gregg W Stone.;David J Maron.;Judith S Hochman.; .
来源: Circulation. 2022年145卷17期1294-1307页
ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) compared an initial invasive treatment strategy (INV) with an initial conservative strategy in 5179 participants with chronic coronary disease and moderate or severe ischemia. The ISCHEMIA research program included a comprehensive quality-of-life (QOL) substudy.
367. Validating an Idiopathic Dilated Cardiomyopathy Diagnosis Using Cardiovascular Magnetic Resonance: The Dilated Cardiomyopathy Precision Medicine Study.
作者: Garrie J Haas.;Karolina M Zareba.;Hanyu Ni.;Erika Bello-Pardo.;Gordon S Huggins.;Ray E Hershberger.; .
来源: Circ Heart Fail. 2022年15卷5期e008877页
Coronary angiography to identify coronary artery disease has been foundational to distinguish the cause of dilated cardiomyopathy (DCM), including the assignment of idiopathic or ischemic cardiomyopathy. Late gadolinium enhancement (LGE) with cardiovascular magnetic resonance (CMR) has emerged as an approach to identify myocardial scar and identify etiology.
368. Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial.
作者: Steven A Lubitz.;Steven J Atlas.;Jeffrey M Ashburner.;Ana T Trisini Lipsanopoulos.;Leila H Borowsky.;Wyliena Guan.;Shaan Khurshid.;Patrick T Ellinor.;Yuchiao Chang.;David D McManus.;Daniel E Singer.
来源: Circulation. 2022年145卷13期946-954页
Undiagnosed atrial fibrillation (AF) may cause preventable strokes. Guidelines differ regarding AF screening recommendations. We tested whether point-of-care screening with a handheld single-lead ECG at primary care practice visits increases diagnoses of AF.
369. Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial.
作者: Tetsuro Yoshida.;Akihiro Nakamura.;Junichi Funada.;Mari Amino.;Wataru Shimizu.;Masayuki Fukuzawa.;Saori Watanabe.;Takuya Hayashi.;Takeshi Yamashita.;Ken Okumura.;Masaharu Akao.
来源: Circulation. 2022年145卷9期718-720页 370. Cytokine Hemoadsorption During Cardiac Surgery Versus Standard Surgical Care for Infective Endocarditis (REMOVE): Results From a Multicenter Randomized Controlled Trial.
作者: Mahmoud Diab.;Thomas Lehmann.;Wolfgang Bothe.;Payam Akhyari.;Stephanie Platzer.;Daniel Wendt.;Antje-Christin Deppe.;Justus Strauch.;Stefan Hagel.;Albrecht Günther.;Gloria Faerber.;Christoph Sponholz.;Marcus Franz.;André Scherag.;Ilia Velichkov.;Miriam Silaschi.;Jens Fassl.;Britt Hofmann.;Sven Lehmann.;Rene Schramm.;Georg Fritz.;Gabor Szabo.;Thorsten Wahlers.;Klaus Matschke.;Artur Lichtenberg.;Mathias W Pletz.;Jan F Gummert.;Friedhelm Beyersdorf.;Christian Hagl.;Michael A Borger.;Michael Bauer.;Frank M Brunkhorst.;Torsten Doenst.; .
来源: Circulation. 2022年145卷13期959-968页
Cardiac surgery often represents the only treatment option in patients with infective endocarditis (IE). However, IE surgery may lead to a sudden release of inflammatory mediators, which is associated with postoperative organ dysfunction. We investigated the effect of hemoadsorption during IE surgery on postoperative organ dysfunction.
371. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.
作者: Remo H M Furtado.;Antônio Aurélio Fagundes.;Kazuma Oyama.;Thomas A Zelniker.;Minao Tang.;Julia F Kuder.;Sabina A Murphy.;Andrew Hamer.;Huei Wang.;Anthony C Keech.;Robert P Giugliano.;Marc S Sabatine.;Brian A Bergmark.
来源: Circ Cardiovasc Interv. 2022年15卷3期e011382页
Patients with prior percutaneous coronary intervention (PCI) are at high residual risk for multiple types of coronary events within and beyond the stented lesion. This risk might be mitigated by more intensive LDL-C (low-density lipoprotein cholesterol)-lowering beyond just with statin therapy.
372. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.
作者: Benjamin E Peterson.;Robert A Harrington.;Gregg W Stone.;Ph Gabriel Steg.;C Michael Gibson.;Christian W Hamm.;Matthew J Price.;Renato D Lopes.;Sergio Leonardi.;Jayne Prats.;Efthymios N Deliargyris.;Kenneth W Mahaffey.;Harvey D White.;Deepak L Bhatt.
来源: Circ Cardiovasc Interv. 2022年15卷3期e011069页
In randomized trials, cangrelor reduced periprocedural ischemic events related to percutaneous coronary intervention without increasing GUSTO severe bleeding. However, some antiplatelet agents have shown a differential treatment effect by body mass index (BMI).
373. Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.
作者: Ivana Semova.;Amy E Levenson.;Joanna Krawczyk.;Kevin Bullock.;Mary E Gearing.;Alisha V Ling.;Kathryn A Williams.;Ji Miao.;Stuart S Adamson.;Dong-Ju Shin.;Satyapal Chahar.;Mark J Graham.;Rosanne M Crooke.;Lee R Hagey.;David Vicent.;Sarah D de Ferranti.;Srividya Kidambi.;Clary B Clish.;Sudha B Biddinger.
来源: Circulation. 2022年145卷13期969-982页
The risk of cardiovascular disease in type 1 diabetes remains extremely high, despite marked advances in blood glucose control and even the widespread use of cholesterol synthesis inhibitors. Thus, a deeper understanding of insulin regulation of cholesterol metabolism, and its disruption in type 1 diabetes, could reveal better treatment strategies.
374. Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2.
作者: Tjerk S J Opstal.;Amber van Broekhoven.;Aernoud T L Fiolet.;Arend Mosterd.;John W Eikelboom.;Stefan M Nidorf.;Peter L Thompson.;Charley A Budgeon.;Louis Bartels.;Ron de Nooijer.;Willem A Bax.;Jan G P Tijssen.;Saloua El Messaoudi.;Jan H Cornel.
来源: Circulation. 2022年145卷8期626-628页 375. MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial.
作者: Karl Georg Haeusler.;Felizitas A Eichner.;Peter U Heuschmann.;Jochen B Fiebach.;Tobias Engelhorn.;Benjamin Blank.;David Callans.;Arif Elvan.;Massimo Grimaldi.;Jim Hansen.;Gerhard Hindricks.;Hussein R Al-Khalidi.;Lluis Mont.;Jens Cosedis Nielsen.;Jonathan P Piccini.;Ulrich Schotten.;Sakis Themistoclakis.;Johan Vijgen.;Luigi Di Biase.;Paulus Kirchhof.
来源: Circulation. 2022年145卷12期906-915页
We aimed to assess the prevalence of ischemic brain lesions detected by magnetic resonance imaging and their association with cognitive function 3 months after first-time ablation using continuous oral anticoagulation in patients with paroxysmal atrial fibrillation (AF).
376. One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial.
作者: Jose R Gonzalez-Juanatey.;Gilles Lemesle.;Etienne Puymirat.;Gregory Ducrocq.;Marine Cachanado.;Joan Albert Arnaiz.;Manuel Martínez-Sellés.;Johanne Silvain.;Albert Ariza-Solé.;Emile Ferrari.;Gonzalo Calvo.;Nicolas Danchin.;Cristina Avendano-Solá.;Alexandra Rousseau.;Eric Vicaut.;Teba Gonzalez-Ferrero.;Philippe Gabriel Steg.;Tabassome Simon.; .
来源: Circulation. 2022年145卷6期486-488页 377. Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial.
作者: Xinxing Lai.;Zhenyu Dong.;Shengxian Wu.;Xiaohua Zhou.;Genming Zhang.;Shangquan Xiong.;Wei Wu.;Rui Cao.;Xiaolong Wang.;Qi Hua.;Jinhang Du.;Jinying Fan.;Jingyuan Mao.;Weimin Jiang.;Huishu Yuan.;Yushan Chen.;Yong Xu.;Zhanquan Li.;Jun Zhang.;Guiying Dong.;Hui Zhen.;Ru Ding.;Zonggui Wu.;Ying Gao.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷3期e007923页
Hypertension is one of the most challenging public health problems worldwide. Previous studies suggested that the Songling Xuemaikang capsule (SXC)-a Chinese herbal formula-was effective for essential hypertension. However, the efficacy of SXC monotherapy for hypertension remains unclear. We aimed to compare the blood pressure (BP)-lowering efficacy and safety of SXC versus losartan in patients with essential hypertension.
378. Genetic European Ancestry and Incident Diabetes in Black Individuals: Insights From the SPRINT Trial.
作者: Vibhu Parcha.;Brittain Heindl.;Rajat Kalra.;Adam Bress.;Shreya Rao.;Ambarish Pandey.;Barbara Gower.;Marguerite R Irvin.;Merry-Lynn N McDonald.;Peng Li.;Garima Arora.;Pankaj Arora.
来源: Circ Genom Precis Med. 2022年15卷1期e003468页
Black individuals have high incident diabetes risk, despite having paradoxically lower triglyceride and higher HDL (high-density lipoprotein) cholesterol levels. The basis of this is poorly understood. We evaluated the participants of SPRINT (Systolic Blood Pressure Intervention Trial) to assess the association of estimated European genetic ancestry with the risk of incident diabetes in self-identified Black individuals.
379. Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction.
作者: Timothy D Henry.;C Noel Bairey Merz.;Janet Wei.;Michel T Corban.;Odayme Quesada.;Sandy Joung.;Christine L Kotynski.;Jian Wang.;Michelle Lewis.;Ann M Schumacher.;Ronnda L Bartel.;Hiroshi Takagi.;Vishal Shah.;Anna Lee.;William K Sietsema.;Douglas W Losordo.;Amir Lerman.
来源: Circ Cardiovasc Interv. 2022年15卷2期e010802页
Coronary microvascular dysfunction results in angina and adverse outcomes in patients with evidence of ischemia and nonobstructive coronary artery disease; however, no specific therapy exists. CD34+ cell therapy increases microvasculature in preclinical models and improves symptoms, exercise tolerance, and mortality in refractory angina patients with obstructive coronary artery disease. The objective of this research was to evaluate the safety, tolerability, and efficacy of intracoronary CD34+ cell therapy in patients with coronary microvascular dysfunction.
380. Sex Differences in Health Status and Clinical Outcomes After Nonprimary Percutaneous Coronary Intervention.
作者: Pranoti G Hiremath.;Thomas Aversano.;John A Spertus.;Cynthia C Lemmon.;Daniel Q Naiman.;Matthew J Czarny.
来源: Circ Cardiovasc Interv. 2022年15卷2期e011308页
Greater insight into sex-based differences in health status can lay the foundation for more equitable health care. This study compares differences in health status of women and men in the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non-Primary Percutaneous Coronary Intervention) undergoing nonprimary percutaneous coronary intervention.
|